These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1894357)

  • 1. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.
    Peeters CC; Tenbergen-Meekes AM; Poolman JT; Beurret M; Zegers BJ; Rijkers GT
    Infect Immun; 1991 Oct; 59(10):3504-10. PubMed ID: 1894357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.
    Peeters CC; Tenbergen-Meekes AM; Evenberg DE; Poolman JT; Zegers BJ; Rijkers GT
    J Immunol; 1991 Jun; 146(12):4308-14. PubMed ID: 2040803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
    Chu RS; McCool T; Greenspan NS; Schreiber JR; Harding CV
    Infect Immun; 2000 Mar; 68(3):1450-6. PubMed ID: 10678959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.
    Granoff DM; Rathore MH; Holmes SJ; Granoff PD; Lucas AH
    Vaccine; 1993; 11 Suppl 1():S46-51. PubMed ID: 8447176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.
    Tontini M; Berti F; Romano MR; Proietti D; Zambonelli C; Bottomley MJ; De Gregorio E; Del Giudice G; Rappuoli R; Costantino P; ; Brogioni G; Balocchi C; Biancucci M; Malito E
    Vaccine; 2013 Oct; 31(42):4827-33. PubMed ID: 23965218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.
    Chu C; Schneerson R; Robbins JB; Rastogi SC
    Infect Immun; 1983 Apr; 40(1):245-56. PubMed ID: 6601061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components.
    Barington T; Skettrup M; Juul L; Heilmann C
    Infect Immun; 1993 Feb; 61(2):432-8. PubMed ID: 7678586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide--protein conjugate vaccine is decreased by admixture of high doses of free saccharide.
    Peeters CC; Tenbergen-Meekes AM; Poolman JT; Zegers BJ; Rijkers GT
    Vaccine; 1992; 10(12):833-40. PubMed ID: 1455909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.
    Lagergard T; Shiloach J; Robbins JB; Schneerson R
    Infect Immun; 1990 Mar; 58(3):687-94. PubMed ID: 2407652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.
    Rubinstein LJ; García-Ojeda PA; Michon F; Jennings HJ; Stein KE
    Infect Immun; 1998 Nov; 66(11):5450-6. PubMed ID: 9784556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate.
    Lu CH; Lee CJ; Kind P
    Infect Immun; 1994 Jul; 62(7):2754-60. PubMed ID: 8005665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children.
    Claesson BA; Trollfors B; Lagergard T; Taranger J; Bryla D; Otterman G; Cramton T; Yang Y; Reimer CB; Robbins JB
    J Pediatr; 1988 May; 112(5):695-702. PubMed ID: 3361379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.
    Lefeber DJ; Benaissa-Trouw B; Vliegenthart JF; Kamerling JP; Jansen WT; Kraaijeveld K; Snippe H
    Infect Immun; 2003 Dec; 71(12):6915-20. PubMed ID: 14638780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid.
    Korkeila M; Lehtonen H; Ahman H; Leroy O; Eskola J; Käyhty H
    Vaccine; 2000 Jan; 18(13):1218-26. PubMed ID: 10649623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.
    Anttila M; Eskola J; Ahman H; Käyhty H
    J Infect Dis; 1998 Jun; 177(6):1614-21. PubMed ID: 9607841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
    Tarkowski A; Lue C; Moldoveanu Z; Kiyono H; McGhee JR; Mestecky J
    J Immunol; 1990 May; 144(10):3770-8. PubMed ID: 2110213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG2 subclass restriction of antibody to pneumococcal polysaccharides.
    Barrett DJ; Ayoub EM
    Clin Exp Immunol; 1986 Jan; 63(1):127-34. PubMed ID: 3955880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.